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PVIEWPOINT
All Is Not Well in the World of Translational Research
Ellis F. Unger, MD
Silver Spring, Maryland
It is not unusual for novel treatment strategies to fail in clinical trials, despite highly encouraging results in pre-
clinical proof-of-concept studies. Typically, such “failures of translation” are blamed on the poor predictiveness of
animal models. Often, however, the poor predictiveness of today’s preclinical proof-of-concept studies is related
not to limitations of the models but to investigator bias and a lack of scientific rigor. The resulting false-positive
results only serve to mislead the field and impede medical progress. With the resurgence of translational re-
search, it is useful to examine some of the problems that plague these studies and consider their solutions. With
thoughtful planning, execution, and analysis, it is possible to generate reliable and predictive data from preclini-
cal proof-of-concept studies, results that should more rapidly advance medical progress. (J Am Coll Cardiol
2007;50:738–40) © 2007 by the American College of Cardiology Foundation






























“elvin Marcus was a giant in academic cardiology, a critical
hinker who appreciated the nuances of preclinical studies.
t scientific meetings, he would provide thoughtful analyses
nd critique to junior (and not-so-junior) scientists. Fre-
uently, he would surprise a speaker (and audience) by
dentifying a crucial issue that had been overlooked by the
nvestigators, throwing a study into doubt. He mentored
ountless young investigators with this insight and wisdom.
ragically, he succumbed to cancer in 1989, at the age of 49
ears.
It is a different time now. Presentations of study results,
ncluding truly fantastic findings, go largely unchallenged at
cientific meetings; in fact, they seem to be readily accepted
s the norm. Investigators induce experimental myocardial
nfarction in rats, and subsequent injection of stem cells into
he tail vein leads to a 30% improvement in left ventricular
jection fraction! Transfer of a gene encoding an angiogenic
ytokine improves collateral perfusion by 40%. The pattern
as been the same for many years now: acceptance of highly
ncouraging results without a thoughtful critique or careful
eighing of study limitations. Similarly, outstanding pre-
linical results often are presented in publications with little
n the way of critical analysis. Viewed optimistically, these
proof-of-concept” studies can serve as a launching pad for
hase 1 studies in human subjects. If the drug or biotech-
ology product appears to be reasonably well tolerated in
hase 1, possibly with some anecdotal evidence of biological
ctivity, a Phase 2 clinical program is initiated. At some
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ccepted April 24, 2007.oint in late-Phase 2, when it becomes clear that the
roduct has no beneficial effect in patients, we blame the
nimal model for deceiving us! We declare that the model
as a poor predictor of human disease.
Much has been written regarding the limitations of
nimal models as predictors of responses in humans. Cer-
ainly, animal studies have unavoidable shortcomings, but
any of their limitations originate, not from the models
hemselves, but instead from “human factors,” i.e., the
esign and interpretation of these studies—by humans.
hat Is Wrong With Translational Research?
hole-animal cardiovascular research was an area of in-
ense interest in the 20th century, importantly advancing
ur understanding of cardiovascular physiology and phar-
acology. But with exciting and rapid advances in molec-
lar biology in the 1980s, whole animal studies seemed
uddenly passé. Costs associated with large animal research
kyrocketed. Research grants became more difficult to ob-
ain. A heightened awareness of animal welfare posed
dditional challenges. Bright and promising cardiovascular
ellows were encouraged to seek training in molecular
iology, not animal physiology. Well-established investiga-
ors in animal research moved on to pursue other endeavors,
nd the pool of qualified mentors dwindled. Now, at least in
art because of these factors, expertise in preclinical animal
nvestigation seems sorely limited. Fewer individuals dem-
nstrate the capability to perform adequate preclinical
proof-of-concept” studies. This lack of proficiency appears
o go unrecognized, possibly because relatively few individ-
als grasp the issues well enough to provide substantive
ritique. Although it may be a bit extreme to declare that the
blind are leading the blind,” it does not seem far-fetched to
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August 21, 2007:738–40 All Is Not Well in Translational Researchespite the enthusiasm for the resurrection of translational
esearch, there is a paucity of individuals with the capacity to
erform or interpret these studies competently.
hat Can Be Done to Improve
reclinical Translational Research?
he preclinical “proof-of-concept” study is a critical element
f translational research. Using an animal model designed to
imic a human disease, the demonstration that a drug or
ntervention has a salutary effect on a surrogate end point
rovides the necessary support to move the treatment strategy
orward into the clinic. Preclinical studies can be largely
xploratory, designed to generate hypotheses, in which case
hey can hardly be called “proof-of-concept,” but they may be
evertheless important. Conversely, well-conceived and de-
igned preclinical investigations, carefully executed and rigor-
usly analyzed, may be suitable for formal hypothesis testing.
he latter type of study is more likely to accurately model
uman disease and less likely to misinform.
The principal challenges in designing, conducting, and
nalyzing preclinical translational research are familiar to
linical trialists: variability and bias. Fortunately, with only
oderate effort, both can be reasonably managed in preclin-
cal studies.
inimizing variability. The tension between variability and
ffect size is common to all translational research: to detect the
onsequences of an intervention, the effect size must overcome
he variability in the model. In contradistinction to clinical
tudies, which typically enroll hundreds or thousands of sub-
ects, preclinical studies with as few as a dozen animals may be
dequately powered to detect the effect of a treatment strategy.
he relative homogeneity of the animals and lack of confound-
ng factors underlie this important difference. In contrast to
linical studies, many aspects of preclinical studies can be
arefully controlled, and it is advantageous to strive for consis-
ency in methods and analyses whenever possible. Such con-
istency serves to limit variability.
Disease-free animals should be derived from a single source,
nd should be approximately the same age. (A case can be
ade for selecting animals of a single gender, depending on
hether gender effects are expected.) All animals should be
xposed to the same handling, housing, bedding, food, and
ater. If surgical procedures are required for the model, the
ame individual, or the same team of individuals, should
onduct the surgery in all animals, particularly if the techniques
re complex (e.g., survival surgery). If refinements in surgical
echnique or improvements in other procedures are antici-
ated, the operator (or team) should hone his or her skills
efore initiating the controlled study. A single individual, or a
onsistent team of individuals, should conduct all treatments
nd all end point assessments.
ias: the obvious and the not so obvious. Investigators
re under tremendous pressure to achieve “positive” results.
ositive results have the potential to lead to publications
hat enhance professional recognition and bring about dersonal advancement. Negative study results may (or may
ot) be extremely important from a scientific standpoint,
ut they do little to advance one’s career. Moreover, it is
ifficult to convince editorial boards of medical journals to
ccept negative studies for publication (negative publication
ias). In the case of translational research, proving the
easibility of an original approach to the treatment of a
isease provides yet another inducement to achieve positive
esults, and proof of feasibility may lead to patents and
ucrative licensing arrangements. These incentives lead to
owerful biases, both conscious and subconscious, with the
otential to undermine a study. Fortunately, the application
f some of the principles of design and analysis familiar to
linical trialists can largely neutralize these biases.
andomization and blinding. It goes without saying that
reclinical proof-of-concept studies should include a con-
urrent control group, almost without exception. Historical
r nonconcurrent control groups are of limited value in
stablishing proof-of-concept. Randomization and blinding
re critical to the interpretation of these studies. Variable
lock randomization is reasonable for small animal studies;
nvestigators do not need to be appraised of the random-
zation scheme. Disparate study agents (active agents and
ehicle) should be indistinguishable, if possible. An experi-
nced investigator who is not directly involved in the project
hould prepare the randomization code and fill a set of
oded, labeled vials. They should retain the password-
rotected treatment code in a secure location. (It is also
dvisable for this individual to mail the randomization code
o an independent party, as a backup in case of unforeseen
ircumstances.) Each animal should receive its treatment
ssignment in sequence, matched to a specific coded vial(s).
It is critical to maintain rigorous blinding of all investigators
hroughout the study. Thus, selection of particular animals and
pplication of surgical techniques (if applicable) should be
arried out without knowledge of treatment assignment. It is
mperative that: 1) investigators are blinded to the identities of
tudy agents; 2) investigators are blinded when end points are
ssessed; and 3) investigators remain blinded during data
rocessing and analysis. This author has heard investigators
xplain that their study end points are entirely objective and
herefore not susceptible to bias. Although this may be true on
ccasion, there are additional, more subtle reasons, as discussed
erein, for maintaining a blinded study.
issing data. Typically, complex preclinical investigations
uffer from missing data (e.g., animal deaths, technical issues).
t is a fact, however, that small studies are exquisitely sensitive
o the effects of missing data; the inclusion or exclusion of a
ingle data point can alter the results and conclusions of a
tudy. Thus, it is critical to have a prospective plan to deal with
issing data and outliers. If decisions must be made regarding
issing data, they must be made without knowledge of
reatment assignment. Although it is less obvious, missing data
lso may arise by choice. For example, decisions regarding
ncillary animal care and treatment are sometimes required
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All Is Not Well in Translational Research August 21, 2007:738–40ffect the study results. Consider a strategy that is hoped to
mprove left ventricular function after experimental myocardial
nfarction. Confronted with an animal in florid heart failure,
reatment decisions have to be made for the benefit of the
nimal. Some might argue that it is best to euthanize the
nimal. Given an animal with a predictably poor study out-
ome, knowledge of treatment assignment could most certainly
ias such decisions. However, even if the investigator is
linded, the judgment to euthanize the animal is tantamount
o consciously changing an outcome from “poor” to “missing.”
epending on the plan for handling missing data, these
ecisions may bias the study and undermine the study results
nd conclusions.
Data outliers pose yet another problem. Consider once
gain the study of acute myocardial infarction. The record-
ng of a left ventricular ejection fraction of 95% in an animal
ith a sizable myocardial infarction is probably spurious. An
jection fraction of 70% may be spurious. Is there some
utoff of unreasonableness, beyond which outliers should be
liminated? If so, standard methods to identify outliers
hould be established prospectively. Finally, in publications
nd presentations, animal deaths and the handling of
issing data and outliers should be discussed with the study
esults, if applicable.
In summary, missing data and outliers can strongly influence
he results of preclinical studies. If there are prospective plans
n place to address these issues, and if decisions are made
ithout knowledge of treatment assignment, there is less
pportunity for bias to influence the study.
tatistics. It is not unusual to observe misuse of statistical
ests in preclinical studies. For example, use of paired t tests to
nalyze unpaired data, and use of parametric methods to
nalyze non-normally distributed data are not uncommon.
ultiplicity is often an issue in preclinical studies that is
nadequately addressed. Consider a study with 2 active treat-
ent groups (2 different routes of administration) and a vehicle
ontrol group, with 2 main end points, each assessed at 3
oints in time. Under these circumstances, there are 12 ways to
win,” and a rigorous statistical approach requires adjustment
f alpha. However, there is nothing inherently wrong with
xploring all possibilities and presenting nominal p values, as
ong as the data are interpreted fairly under the guise of an
xploratory study. Alternatively, the prespecification of a single
rimary end point and a single time for its assessment would
liminate much of this multiplicity, such that the statistical
lan would only have to account for the fact that there are 2
ctive treatment groups.
tudy limitations. All studies have limitations. The typical
eader may not be an expert in the field and may lack the
Mophistication necessary to ferret out a study’s pitfalls. The
imitations section of the paper should present a clear, honest,
nformative, and balanced view of the data and their interpre-
ation. A less-balanced “devil’s advocate” perspective on the
tudy’s limitations and interpretations can be very informative
s well. If animals died or were otherwise excluded, this result
hould be explained. Missing data that may have compromised
he results should be discussed. If this was an exploratory study
e.g., if 5 end points were analyzed without priority and
ithout adjustment of alpha) this should be stated. If there was
otential unblinding during the course of the study, perhaps
ecause of a blood pressure-lowering effect of the active
reatment, this should be explained. The usual “disclaimer”
anguage, that the particular animal model may have limita-
ions in predicting effects in humans with disease, may be true,
ut it is not particularly useful.
ubstantiation of findings. Positive findings in a single
tudy should be independently substantiated by a subsequent
tudy. Given the strength of the biases that are operational
uring preclinical proof-of-concept studies (both conscious
nd unconscious), the frequency of a false-positive result may
e substantially greater than the 5% “guaranteed” by a nominal
value of 0.05. These biases exist despite the best intentions of
he investigators. Substantiation is neither as impractical nor as
ifficult as it sounds. Subsequent studies can be designed to
xtend the results of a previous study, while also substantiating
hem. By examining alternative modes of drug delivery, alter-
ng the timing of drug delivery or, in particular, studying higher
r lower doses of the study agent, critical incremental knowl-
dge can be gained, while at the same time substantiating the
nitial results. There is also much value in comparing the test
gent head-to-head with another agent that has known bio-
ogical activity. Although such follow-up studies may seem
nherently less exciting than the initial study, they are never-
heless important.
onclusions
ith careful planning, rigorous execution, and thoughtful
nalysis, valid and persuasive data can be obtained from
reclinical proof-of-concept studies. Through the applica-
ion of the aforementioned principles, false-positive results
ill be less likely to misguide investigators, and the field will
e advanced more rapidly.
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